Considerations for the Use of Cytokine-Secreting Tumor Cell Preparations for Cancer Treatment
Authors:
- 1 January 1995
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 13 (2) , 193-201
Abstract
Limited efficacy of chemotherapy in most solid tumors has revived interest in immunotherapeutic approaches for cancer. One novel form of immunotherapy is the use of cancer vaccines consisting of tumor cells genetically engineered to secrete cytokines. The rationale for this immunization strategy is based on the existence of tumor-specific antigens, on the importance of the cellular arm of the immune system in mediating an effective antitumor response, and on the role of cytokines in regulating the cellular immune response. Such tumor vaccines showed considerable promise in various animal models and induced potent antitumor immunity in the host, which led to regression of established tumors and, moreover, produced immunological memory protecting animals from a subsequent tumor challenge at a distant site. Translated to the human patient, this implies that genetically modified tumor vaccines may be able to eradicate or reduce existing tumor deposits to subclinical levels as well as provide long-term protection from regrowth of tumor cells. This report will review and discuss the concept and rationale for the use of cytokine-secreting tumor vaccines for the treatment of human malignancies.Keywords
This publication has 50 references indexed in Scilit:
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Adenovirus–mediated in vivo gene transfer and expression in normal rat liverNature Genetics, 1992
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Adoptively Transferred Tumor-Infiltrating Lymphocytes Can Cure Established Metastatic Tumor in Mice and Persist Long-Term In Vivo as Functional Memory T LymphocytesJournal of Immunotherapy, 1991
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991
- Antigen Recognition by Class I-Restricted T LymphocytesAnnual Review of Immunology, 1989
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T help.Journal of Experimental Medicine, 1978